drugset / Trial / NCT03208257

Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2

NCT03208257

NaSingle-groupOpen-labelTreatment

Summary

Septic shock is a common syndrome caused by the body's response to an infection. Septic shock is responsible for 10% of all ICU admissions and 30% of ICU deaths. Use of "beta blocker" medications may improve outcomes after septic shock. This pilot study evaluates protocols to infuse the beta blocker esmolol in patients with septic shock.

Timeline

Start
2017-08-07
Primary completion
2020-12
Completion
2021-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Esmolol Other / unclassified 10 ug/kg Intravenous
Subject Esmolol Other / unclassified 40 ug/kg Intravenous